Tag: Artivion
EACTS 2025 hears new data on aortic arch remodelling device
Data from the AMDS PERSEVERE and PROTECT trials—both assessing the use of the Ascyrus medical dissection stent (AMDS, Artivion)—were presented in late-breaking science presentations...
Artivion granted FDA humanitarian device exemption for the AMDS hybrid prosthesis
Artivion recently announced that the Food and Drug Administration (FDA) has granted a humanitarian device exemption (HDE) for use of the AMDS hybrid prosthesis...
Enrollment begins in PERSEVERE clinical trial of hybrid prothesis for aortic...
Artivion announced today that it has initiated enrollment in the PERSEVERE clinical trial to determine if patients with an acute DeBakey Type I aortic dissection...